Therapeutic effects of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: From outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progression and atrial cardiomyopathy

European Journal of Heart FailureEarly View Invited Editorial Therapeutic effects of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: from outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progression and atrial cardiomyopathy Giuseppe Boriani, Corresponding Author Giuseppe Boriani [email protected] Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy Corresponding author. Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41124 Modena, Italy. Email: [email protected]Search for more papers by this authorDavide A. Mei, Davide A. Mei Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorJacopo F. Imberti, Jacopo F. Imberti Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this author Giuseppe Boriani, Corresponding Author Giuseppe Boriani [email protected] Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy Corresponding author. Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41124 Modena, Italy. Email: [email protected]Search for more papers by this authorDavide A. Mei, Davide A. Mei Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this authorJacopo F. Imberti, Jacopo F. Imberti Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, ItalySearch for more papers by this author First published: 16 May 2023 https://doi.org/10.1002/ejhf.2891 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.2861. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 2017; 5: 565– 574. https://doi.org/10.1016/j.jchf.2017.05.001 2Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation 2020; 141: 4– 6. https://doi.org/10.1161/CIRCULATIONAHA.119.042996 3DeSa T, Gong T. SGLT2 inhibitors: A new pillar of the heart failure regimen. Rev Cardiovasc Med 2021; 22: 1253– 1269. https://doi.org/10.31083/j.rcm2204133 4Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace 2021; 23: 1873– 1891. https://doi.org/10.1093/europace/euab184 5Filippatos G, Farmakis D, Butler J, Zannad F, Ferreira JP, Ofstad AP, et al. EMPEROR-Preserved Trial Committees and Investigators. Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation. Eur J Heart Fail . https://doi.org/10.1002/ejhf.2861 Published online ahead of print 16/04/23. 6Boriani G, Vitolo M, Lane DA, Potpara TS, Lip GY. Beyond the 2020 guidelines on atrial fibrillation of the European Society of Cardiology. Eur J Intern Med 2021; 86: 1– 11. https://doi.org/10.1016/j.ejim.2021.01.006 7Meyer M, Lustgarten D. Beta-blockers in atrial fibrillation – trying to make sense of unsettling results. Europace 2023; 25: 260– 262. https://doi.org/10.1093/europace/euad010 8Tsai WH, Chuang SM, Liu SC, Lee CC, Chien MN, Leung CH, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis. Sci Rep 2021; 11:15364. https://doi.org/10.1038/s41598-021-94945-4 9Boriani G, Vitolo M, Diemberger I, Proietti M, Valenti AC, Malavasi VL, et al. Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes. Cardiovasc Res 2021; 117: 1– 21. https://doi.org/10.1093/cvr/cvab147 10Malavasi VL, Fantecchi E, Tordoni V, Melara L, Barbieri A, Vitolo M, et al. Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation. Intern Emerg Med 2021; 16: 1131– 1140. https://doi.org/10.1007/s11739-020-02551-5 11Pallisgaard J, Greve AM, Lock-Hansen M, Thune JJ, Fosboel EL, Devereux RB, et al. Atrial fibrillation onset before heart failure or vice versa: What is worst? A nationwide register study. Europace 2023; 25: 283– 290. https://doi.org/10.1093/europace/euac186 12Ong HT, Teo YH, Teo YN, Syn NL, Wee CF, Leong S, et al. Effects of sodium/glucose cotransporter inhibitors on atrial fibrillation and stroke: A meta-analysis. J Stroke Cerebrovasc Dis 2022; 31:106159. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106159 13Aziri B, Begic E, Jankovic S, Mladenovic Z, Stanetic B, Kovacevic-Preradovic T, et al. Systematic review of sodium-glucose cotransporter 2 inhibitors: A hopeful prospect in tackling heart failure-related events. ESC Heart Fail 2023; 10(3): 1499– 1530. https://doi.org/10.1002/ehf2.14355 Published online ahead of print 26/03/23. 14Boriani G, Imberti JF, Vitolo M. The burden of atrial fibrillation in patients with preserved or mildly reduced heart failure: A call to action for detecting atrial fibrillation and improving outcome. Eur J Heart Fail 2023; 25: 74– 76. https://doi.org/10.1002/ejhf.2755 15Karamichalakis N, Kolovos V, Paraskevaidis I, Tsougos E. A new hope: Sodium-glucose cotransporter-2 inhibition to prevent atrial fibrillation. J Cardiovasc Dev Dis 2022; 9:236. https://doi.org/10.3390/jcdd9080236 16Donniacuo M, De Angelis A, Telesca M, Bellocchio G, Riemma MA, Paolisso P, et al. Atrial fibrillation: Epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors. Pharmacol Res 2023; 188:106591. https://doi.org/10.1016/j.phrs.2022.106591 17Boriani G, Vitolo M, Imberti JF. Atrial cardiomyopathy: A derangement in atrial volumes, geometry, function, and pathology with important clinical implications. J Cardiovasc Med (Hagerstown) 2022; 23: 359– 362. https://doi.org/10.2459/JCM.0000000000001316 18Marra AM, Bencivenga L, D'Assante R, Rengo G, Cittadini A. Heart failure with preserved ejection fraction: Squaring the circle between comorbidities and cardiovascular abnormalities. Eur J Intern Med 2022; 99: 1– 6. https://doi.org/10.1016/j.ejim.2022.01.019 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation